Use of Circulating Exosomal LncRNA-GC1 to Monitor Gastric Cancer
NCT ID: NCT05397548
Last Updated: 2022-06-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
700 participants
OBSERVATIONAL
2022-05-01
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Although its incidence and mortality has decreased, gastric cancer (GC) is the fourth most common cancer and the second leading cause of cancer-related death worldwide, particularly in China. The number of new cases and deaths may comprise approximately one-half of the global total. The high mortality of GC is partially attributed to late detection and nonspecific symptoms. The current gold standard for diagnosing GC is endoscopic biopsy. However, because of its discomfort to the patient and high cost, screening for early GC (EGC) is a major difficulty in clinical practice, particularly for asymptomatic individuals. Unfortunately, gastric precursor lesions such as intestinal metaplasia (IM), chronic atrophic gastritis (CAG), and persistent Helicobacter pylori (HP) infection increase the difficulty of screening for EGC. Furthermore, the standard serum biomarkers for GC, such as CEA, CA72-4, and CA19-9 achieve a low positive rate. Thus, it is critically important to develop new approaches for diagnosing EGC with high specificity and sensitivity.
Objective:
To study circulating exosomal lncRNA-GC1 as a potential biomarker for detection of gastric cancer.
Eligibility:
Participants from two medical centers in China
Design:
Investigators will use blood samples from participants in the two medical centers. Investigators will use samples from some who developed gastric cancer. The other samples will be from some who stayed cancer free in that time.
Participants already gave written informed consent.
Investigators will take exosomes from the samples and look for lncRNA-GC1.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prospectively Predict the Immunotherapy Response of Gastric Cancer Based on Circulating Exosomal LncRNA-GC1 Biopsy
NCT05334849
Use of a Liquid Biopsy Signature to Detect Early-onset Gastric Cancer
NCT06023121
Screening of Small Non-coding RNAs as an Auxiliary Diagnostic Biomarker for Gastric Cancer
NCT06776835
Gastric Cancer Early Detection by Multi-dimensional Analysis of cfDNA
NCT05668910
Detection of CTC and ctDNA in the Diagnosis of Metastasis in Gastric Cancer
NCT05208372
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
case
Gastric cancer cases from two medical centers in China
Measurement of levels of circulating exosomal lncRNA-GC1
Each participant was enrolled to assess the levels of circulating exosomal lncRNA-GC1
control
Controls from two medical centers in China
Measurement of levels of circulating exosomal lncRNA-GC1
Each participant was enrolled to assess the levels of circulating exosomal lncRNA-GC1
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Measurement of levels of circulating exosomal lncRNA-GC1
Each participant was enrolled to assess the levels of circulating exosomal lncRNA-GC1
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ageā„ 18 years old
* Histologically confirmed gastric adenocarcinoma
Exclusion Criteria
* Surgery (excluding diagnostic biopsy) within 4 weeks prior to study
* Pregnancy or lactation period
* Legal incapacity
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Xijing Hospital
OTHER
Lin Chen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Lin Chen
Vice Director of Department of General Surgery, Chinese PLA General Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Qiying Song, MD
Role: STUDY_DIRECTOR
Chinese PLA General Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Xinxin Wang
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GC-biomarker
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.